SCHEMBL9922782

SCHEMBL9922782

Cc1cc(S(=O)(=O)NC(=O)Nc2ccc(-n3c4c(c5ccccc5c3=O)CN(C)C4)cc2)sc1Cl

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.43
PPARG P37231 3/20 0.38
KDM4E B2RXH2 2/20 0.37
MAPT P10636 2/20 0.37
CA12 O43570 4/20 0.35
CA9 Q16790 4/20 0.35
CA1 P00915 3/20 0.35
TP53 P04637 1/20 0.33
CA2 P00918 2/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
RAB9A P51151 1/20 0.33
PTGER3 P43115 2/20 0.32
ABCB1 P08183 1/20 0.32
LMNA P02545 1/20 0.31
IDH1 O75874 2/20 0.31
CASP3 P42574 1/20 0.31
CASP7 P55210 1/20 0.31
KDR P35968 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12161551 0.93 P2RY12 (0.43) P2RY12PPARGKDM4EMAPTCA12
SCHEMBL9923097 0.87 P2RY12 (0.52) P2RY12PPARGKDM4EMAPTTP53
SCHEMBL9922779 0.87 P2RY12 (0.45) P2RY12PPARGKDM4EMAPTCA12
SCHEMBL12161552 0.78 P2RY12 (0.44) P2RY12PPARGKDM4EMAPTCA12
SCHEMBL9922823 0.78 P2RY12 (0.46) P2RY12MAPTCA12CA9CA1
SCHEMBL9922313 0.76 P2RY12 (0.42) P2RY12KDM4EMAPTCA12CA9
SCHEMBL12177234 0.75 CA12 (0.35) P2RY12PPARGKDM4ECA12CA9
SCHEMBL9923095 0.73 P2RY12 (0.53) P2RY12PPARGKDM4EMAPTALDH1A1
SCHEMBL9922869 0.73 P2RY12 (0.37) P2RY12PPARGKDM4ECA12CA9
SCHEMBL12161522 0.72 P2RY12 (0.44) P2RY12PPARGKDM4EMAPTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 19/4885PPARG 312/4885KDM4E 2302/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 18/4885PPARG 301/4885KDM4E 2312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.